Press Releases

– Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Apr. 1, 2024-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications

SEATTLE --(BUSINESS WIRE)--Mar. 27, 2024-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023 , on Monday, April 1, 2024 , after the market closes. Omeros management will host a conference call and

SEATTLE --(BUSINESS WIRE)--Feb. 20, 2024-- Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

– Expands DRI royalty deal on U.S. net sales of OMIDRIA – – Expanded deal brings Omeros $115 million upfront payment and opportunity for additional $55 million in sales-based milestones – SEATTLE --(BUSINESS WIRE)--Feb. 1, 2024-- Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI